Lea Burke

PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

Ethan Basch, Bryce B. Reeve, Charles S. Cleeland et al. · Value in Health · 2010 · 163 citations

Health Professions, Oncology, Clinical Classification Systems +12

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T. Maziarz, Jae H. Park et al. · Blood · 2023 · 16 citations

Life Sciences, Immunology, Pharmacology +14

Trial in Progress: A Phase 2, Single-Arm, Open-Label Study of Itacitinib (ITA) for the Prevention of Chimeric Antigen Receptor (CAR) T-Cell–Induced Cytokine Release Syndrome (CRS)

Jae H. Park, Matthew J. Frigault, Richard T. Maziarz et al. · Biology of Blood and Marrow Transplantation · 2020 · 11 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study

Matthew J. Frigault, Richard T. Maziarz, Jae H. Park et al. · Blood · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael A. Pratta, Lea Burke, John F. DiPersio et al. · Blood · 2022 · 10 citations

Life Sciences, Oncology, Pharmacology +14